NeuroSense Therapeutics
NeuroSense Therapeutics is a clinical-stage biotech company focused on discovering and developing targeted therapeutics for neurodegenerative diseases, especially ALS. Founded in 2017, the company aims to create combined therapeutic strategies targeting multiple mechanisms involved in these complex diseases. Their lead drug candidate, PrimeC, has shown promising results in clinical trials, including slowing disease progression and increasing survival in ALS patients. NeuroSense collaborates with various partners and is committed to patient-centric approaches, community engagement, and advancing treatments to improve lives.
Industries
Nr. of Employees
small (1-50)
NeuroSense Therapeutics
Products
Oral fixed‑dose combination therapeutic candidate (ciprofloxacin + celecoxib)
An oral fixed‑dose combination of two previously approved small molecules formulated with delayed/synchronized release to target multiple disease mechanisms in neurodegenerative disorders; advanced through preclinical models and Phase 2b clinical evaluation for ALS.
Oral fixed‑dose combination therapeutic candidate (ciprofloxacin + celecoxib)
An oral fixed‑dose combination of two previously approved small molecules formulated with delayed/synchronized release to target multiple disease mechanisms in neurodegenerative disorders; advanced through preclinical models and Phase 2b clinical evaluation for ALS.
Services
In‑house clinical development programs
End‑to‑end clinical development of therapeutics for neurodegenerative diseases, including conducting Phase 2b randomized trials and preparing pivotal Phase 3 studies; trial site coordination and participant management.
In‑house clinical development programs
End‑to‑end clinical development of therapeutics for neurodegenerative diseases, including conducting Phase 2b randomized trials and preparing pivotal Phase 3 studies; trial site coordination and participant management.
Expertise Areas
- Clinical trial management
- Neurodegenerative disease drug development
- Combination therapy formulation and CMC
- Preclinical model development (iPSC, zebrafish, tissue culture)
Key Technologies
- Fixed‑dose combination oral formulation
- Delayed/sustained‑release oral delivery
- iPSC disease models
- Zebrafish neuroprotection models